WWM
IBRX icon

Western Wealth Management’s ImmunityBio IBRX Stock Holding History

Western Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,470
Closed -$103K – 675
2023
Q4 		$103K Sell
20,470
-325
-2% -$1.02K 0.01% 679
2023
Q3 		$35.1K Hold
20,795
– – ﹤0.01% 645
2023
Q2 		$57.8K Buy
+20,795
New +$58.8K ﹤0.01% 634

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Western Wealth Management's IBRX Position: Q1 2024 in Review

Western Wealth Management sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 20,470 shares — an estimated $103K sold.

Western Wealth Management first reported a position in IBRX in Q2 2023 and held it in 3 quarters. The position peaked at $103K in Q4 2023. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

  • Western Wealth Management reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
  • Western Wealth Management sold 20,470 ImmunityBio shares in Q1 2024, an estimated $103K.
  • Western Wealth Management first reported a position in ImmunityBio in Q2 2023 and held it in 3 quarters.
  • Western Wealth Management's ImmunityBio position peaked at $103K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Western Wealth Management's 13F filing for Q1 2024, filed 3 May 2024.